

John B Kisiel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4234667/publications.pdf>

Version: 2024-02-01

102
papers

2,513
citations

186209

28
h-index

223716

46
g-index

105
all docs

105
docs citations

105
times ranked

3348
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e508-e528.	2.4	36
2	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 173-182.e7.	2.4	62
3	Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes. , 2022, 1, 55-62.		1
4	Multicancer early detection test: Preclinical, translational, and clinical evidenceâ€“generation plan and provocative questions. <i>Cancer</i> , 2022, 128, 861-874.	2.0	7
5	Multicancer early detection: International summit to Clarify the Roadmap. <i>Cancer</i> , 2022, 128, 859-860.	2.0	0
6	Discovery and Validation of Methylated DNA Markers From Pancreatic Neuroendocrine Tumors. , 2022, 1, 409-416.		0
7	Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. <i>Gynecologic Oncology</i> , 2022, 165, 568-576.	0.6	10
8	Assessment of extracellular vesicle isolation methods from human stool supernatant. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12208.	5.5	14
9	High Positive Predictive Value of Multi-Target Stool DNA After Aerodigestive Tract Radiotherapy. , 2022, , .		0
10	Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. <i>Pancreatology</i> , 2022, , .	0.5	0
11	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2597-2605.e4.	2.4	73
12	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 594-602.	0.9	6
13	Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 616-617.	2.4	58
14	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. <i>Clinical Cancer Research</i> , 2021, 27, 141-149.	3.2	17
15	Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45â€“49 Year-Olds: A Cross-Sectional Study. <i>Cancer Prevention Research</i> , 2021, 14, 489-496.	0.7	26
16	Recent trends in colorectal cancer screening methods based on Medicare claims data. <i>Current Medical Research and Opinion</i> , 2021, 37, 605-607.	0.9	7
17	High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. <i>Clinical Cancer Research</i> , 2021, 27, 2523-2532.	3.2	17
18	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. <i>Cancer Prevention Research</i> , 2021, 14, 573-580.	0.7	16

#	ARTICLE	IF	CITATIONS
19	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021, 5, 1448-1459.	2.0	8
20	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	1
21	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. <i>American Journal of Gastroenterology</i> , 2021, 116, 1620-1631.	0.2	18
22	Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer. <i>Journal of Gastroenterology</i> , 2021, 56, 659-672.	2.3	7
23	Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00375.	1.3	3
24	Using cell-free DNA for HCC surveillance and prognosis. <i>JHEP Reports</i> , 2021, 3, 100304.	2.6	27
25	Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 498-505.	0.5	17
26	Vulvar Crohn's Disease: Clinical Features and Outcomes. <i>American Journal of Gastroenterology</i> , 2021, 116, 2296-2299.	0.2	5
27	Integrating Genome and Methylome Data to Identify Candidate DNA Methylation Biomarkers for Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2079-2087.	1.1	10
28	Low Incidence of Aerodigestive Cancers in Patients With Negative Results From Colonoscopies, Regardless of Findings From Multitarget Stool DNA Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 864-871.	2.4	18
29	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 520-521.	2.4	0
30	Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 676-683.e3.	2.4	40
31	Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. <i>Gynecologic Oncology</i> , 2020, 156, 387-392.	0.6	22
32	Methylated DNA Markers of Esophageal Squamous Cancer and Dysplasia: An International Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2642-2650.	1.1	7
33	Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1201-1209.	0.2	28
34	Colorectal Cancer Screening With the Multitarget Stool DNA Test. <i>American Journal of Gastroenterology</i> , 2020, 115, 1737-1740.	0.2	8
35	Comparison of Tissue-Based Molecular Markers in Younger versus Older Patients with Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1570-1576.	1.1	4
36	Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy. <i>Current Gastroenterology Reports</i> , 2020, 22, 32.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy. <i>American Journal of Gastroenterology</i> , 2020, 115, 608-615.	0.2	17
38	Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 109-119.	0.3	21
39	Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis. <i>MBio</i> , 2020, 11, .	1.8	101
40	Multitarget Stool DNA for Average Risk Colorectal Cancer Screening. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 553-568.	0.6	7
41	Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4577-4577.	0.8	3
42	Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia. <i>Epigenomics</i> , 2020, 12, 2173-2187.	1.0	3
43	Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 914-921.e5.	2.4	35
44	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1171.	1.0	10
45	Circulating Tumor DNA and Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2019, 39, 452-462.	1.8	27
46	1078 “ Methylated Dna Markers Detect Esophageal Squamous Dysplasia in Mucosal Tissue and When Sampled by Nonendoscopic Esophageal Balloons: An Exploratory Study. <i>Gastroenterology</i> , 2019, 156, S-227-S-228.	0.6	1
47	Tu1015 “ Multi-Target Stool Dna Testing: Yield As a Function of Time Since Last Colonoscopy. <i>Gastroenterology</i> , 2019, 156, S-947-S-948.	0.6	2
48	Su1664 “ High Yield of Total and Right-Sided Colorectal Neoplasia by Multi-Target Stool Dna Testing in Average Risk Patients Irrespective of Prior Screening. <i>Gastroenterology</i> , 2019, 156, S-602-S-603.	0.6	3
49	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. <i>Crohn's & Colitis 360</i> , 2019, 1, .	0.5	2
50	Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. <i>Cancer Prevention Research</i> , 2019, 12, 821-830.	0.7	13
51	Sa1042 MULTI-TARGET STOOL DNA TESTING ENRICHES DETECTION OF COLORECTAL NEOPLASIA BY COLONOSCOPY BUT YIELD IS INFLUENCED BY BASELINE POLYP DETECTION RATES. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB149-AB150.	0.5	5
52	Response to “Colorectal Cancer Screening by Stool DNA Testing and Patient Emotional Health” <i>American Journal of Gastroenterology</i> , 2019, 114, 829-830.	0.2	1
53	Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. <i>American Journal of Gastroenterology</i> , 2019, 114, 1539-1549.	0.2	43
54	325“Novel Multi-Target Stool DNA Marker Panel Yields Highly Accurate Detection of Colorectal Cancer and Premalignant Neoplasia. <i>American Journal of Gastroenterology</i> , 2019, 114, S191-S191.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. <i>Clinical Cancer Research</i> , 2019, 25, 7396-7404.	3.2	33
56	Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. <i>Hepatology</i> , 2019, 69, 1180-1192.	3.6	138
57	Multi-Target DNA Aberrations in Sporadic Colorectal Cancer Tissues Do Not Differ Between Younger and Older Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, S160-S160.	0.2	2
58	Response. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 444.	0.5	1
59	Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 273-278.	0.6	8
60	Outcomes of Endoscopic Therapy for Luminal Strictures in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1575-1581.	0.9	26
61	Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. <i>Obesity Surgery</i> , 2018, 28, 1007-1014.	1.1	27
62	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	3.6	45
63	Multi-Target Stool DNA Testing in Patients at Increased Risk for Colorectal Neoplasia Shows Similar Positive Predictive Value to Average Risk Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, S162.	0.2	1
64	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	0.6	67
65	Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. <i>Clinical Cancer Research</i> , 2018, 24, 5724-5734.	3.2	43
66	Screening for esophageal squamous cell carcinoma: recent advances. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 413-426.	0.5	186
67	Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1582-1588.	0.9	31
68	372 - Detection of Esophageal Cancer by Assay of Novel Methylated DNA Markers in Plasma. <i>Gastroenterology</i> , 2018, 154, S-87.	0.6	2
69	393 - Multi-Site Gastrointestinal Cancer Detection by Stool DNA. <i>Gastroenterology</i> , 2018, 154, S-95.	0.6	3
70	Mo1748 - Validation of Novel Methylated DNA Markers for the Detection of Esophageal Squamous Cell Carcinoma and Dysplasia: Multi-National Tissue Study. <i>Gastroenterology</i> , 2018, 154, S-794-S-795.	0.6	2
71	A Comprehensive Approach to Sequence-oriented IsomiR annotation (CASMIIR): demonstration with IsomiR profiling in colorectal neoplasia. <i>BMC Genomics</i> , 2018, 19, 401.	1.2	31
72	Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 614-621.	1.1	29

#	ARTICLE	IF	CITATIONS
73	Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening. <i>Mayo Clinic Proceedings</i> , 2017, 92, 726-733.	1.4	14
74	Detection of Cholangiocarcinoma by Assay of Methylated DNA Markers in Plasma. <i>Gastroenterology</i> , 2017, 152, S1041-S1042.	0.6	5
75	Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 515-529.	1.0	14
76	Colorectal cancer is increased in chronic liver diseases: Is surveillance the answer?. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 105-106.	0.5	0
77	Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1985-1994.	1.1	29
78	Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 657-665.e1.	0.5	40
79	Abstract 712: Detection of lung cancer by assay of novel methylated DNA markers in plasma. <i>Cancer Research</i> , 2017, 77, 712-712.	0.4	5
80	DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1559-1567.	0.9	27
81	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1778-1787.e8.	2.4	12
82	307 Novel Methylated DNA Markers for the Detection of Colorectal Neoplasia in Lynch Syndrome. <i>Gastroenterology</i> , 2016, 150, S70.	0.6	2
83	Endoscopic overestimation of colorectal polyp size. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 201-208.	0.5	74
84	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1005-1012.	0.5	39
85	Editorial: Clarity and Caution in the Natural History of Low-Grade Dysplasia in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 1473-1474.	0.2	1
86	Molecular markers for colorectal cancer screening. <i>Gut</i> , 2015, 64, 1485-1494.	6.1	100
87	New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. <i>Clinical Cancer Research</i> , 2015, 21, 4473-4481.	3.2	108
88	Sa1921 Molecular Detection of Colorectal Neoplasia: Do Markers That Target Acquired DNA Alterations in Sporadic Cases Also Discriminate Lynch Syndrome Cases?. <i>Gastroenterology</i> , 2015, 148, S-355.	0.6	1
89	Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1408-1417.	1.9	79
90	Stool Methylated DNA Markers Decrease Following Colorectal Cancer Resection—Implications for Surveillance. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1764-1767.	1.1	18

#	ARTICLE	IF	CITATIONS
91	109 Discovery of Novel DNA Methylation Markers for the Detection of Colorectal Neoplasia: Selection by Methylome-Wide Analysis. <i>Gastroenterology</i> , 2014, 146, S-30.	0.6	7
92	Su1340 Detection of Colorectal Cancer and Polyps in Patients With Inflammatory Bowel Disease by Novel Methylated Stool DNA Markers. <i>Gastroenterology</i> , 2014, 146, S-440-S-441.	0.6	3
93	769 Novel Methylated DNA Markers Predict Site of Gastrointestinal Cancer. <i>Gastroenterology</i> , 2013, 144, S-84.	0.6	4
94	Cytomegalovirus Infection of the Ileoanal Pouch. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2394-2399.	0.9	66
95	Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 371-380.	1.4	16
96	Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 546-554.	1.9	65
97	Methylated Eyes Absent 4 (EYA4) Gene Promotor in Non-neoplastic Mucosa of Ulcerative Colitis Patients with Colorectal Cancer. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2079-2083.	0.9	12
98	Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2013, 04, 1000145.	0.4	15
99	Stool DNA testing for the detection of pancreatic cancer. <i>Cancer</i> , 2012, 118, 2623-2631.	2.0	110
100	Outcome of Sporadic Adenomas and Adenoma-Like Dysplasia in Patients with Ulcerative Colitis Undergoing Polypectomy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 226-235.	0.9	67
101	Methylated Eya4 Gene in Non-Neoplastic Mucosa of Ulcerative Colitis Patients With Colorectal Cancer: Evidence for a Field Effect. <i>Gastroenterology</i> , 2011, 140, S-348-S-349.	0.6	3
102	Stool DNA Screening for Colorectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 301-308.	1.1	13